PAMAM dendrimers as delivery agents for antisense oligonucleotides

被引:107
作者
Yoo, H [1 ]
Sazani, P [1 ]
Juliano, RL [1 ]
机构
[1] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
关键词
dendrimers; antisense; drug delivery; splicing; luciferase;
D O I
10.1023/A:1018926605871
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To investigate the potential use of PAMAM dendrimers for the delivery of antisense oligonucleotides into cells under conditions that mimic the in vivo environment. Methods. We used HeLa cells stably transfected with plasmid pLuc/705 which has a luciferase gene interrupted by a human beta-globin intron mutated at nucleotide 705, thus causing incorrect splicing. An antisense oligonucleotide overlapping the 705 splice site, when delivered effectively, corrects splicing and allows luciferase expression. The ability of dendrimers to deliver oligonucleotides to HeLa Luc/705 cells was evaluated in the absence or presence of serum. Results. PAMAM dendrimers formed stable complexes with oligonucleotides that had modest cytotoxicity and showed substantial delivery activity. The dose of the oligonucleotide, the charge ratio of oligonucleotide to dendrimer, and the size (generation) of the dendrimers were all critical variables for the antisense effect. The physical properties of dendrimer/oligonucleotide complexes were further investigated using sedimentation and gel electrophoresis methods. Effective oligonucleotide/generation 5 dendrimer complexes were macromolecular rather than particulate in nature, and were not sedimented at 100,000 RPM. Compared to other types of delivery agents, PAMAM dendrimers were more effective in delivering oligonucleotides into the nucleus of cells in the presence of serum proteins. Conclusions. Our results suggest that PAMAM dendrimers form non-particulate delivery complexes that function in the presence of serum proteins and thus may be suited for in vivo therapeutic applications.
引用
收藏
页码:1799 / 1804
页数:6
相关论文
共 40 条
[1]   Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence [J].
Abdou, S ;
Collomb, J ;
Sallas, F ;
Marsura, A ;
Finance, C .
ARCHIVES OF VIROLOGY, 1997, 142 (08) :1585-1602
[2]  
Alahari SK, 1998, J PHARMACOL EXP THER, V286, P419
[3]  
Alahari SK, 1996, MOL PHARMACOL, V50, P808
[4]  
BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
[5]   Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular BioVector (SMBV) [J].
Berton, M ;
Sixou, S ;
Kravtzoff, R ;
Dartigues, C ;
Imbertie, L ;
Allal, C ;
Favre, G .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1997, 1355 (01) :7-19
[6]   Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers [J].
Bielinska, A ;
KukowskaLatallo, JF ;
Johnson, J ;
Tomalia, DA ;
Baker, JR .
NUCLEIC ACIDS RESEARCH, 1996, 24 (11) :2176-2182
[7]  
CARMICHAEL J, 1987, CANCER RES, V47, P943
[8]   Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties [J].
Chaloin, L ;
Vidal, P ;
Lory, P ;
Méry, J ;
Lautredou, N ;
Divita, G ;
Heitz, F .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 243 (02) :601-608
[9]   Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations [J].
Cho, MJ ;
Juliano, R .
TRENDS IN BIOTECHNOLOGY, 1996, 14 (05) :153-158
[10]   pH-Sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples [J].
De Oliveira, MC ;
Fattal, E ;
Couvreur, P ;
Lesieur, P ;
Bourgaux, C ;
Ollivon, M ;
Dubernet, C .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1998, 1372 (02) :301-310